|Eligible Active Ingredient:||Triamcinolone. As a topical paste/lotion containing not more than 0.1%|
|With Effective From:||1-Jun-17|
|Indication Permitted:||For the treatment of mouth ulcers|
|Maximum Daily Dose:||Criteria Not Specified|
|Maximum Supply per Transaction:||Criteria Not Specified|
|Minimum Age of User:||Criteria Not Specified|
|Patient Information Leaflet from HSA/PSS:||Download PIL (Link to HSA website)|
Mechanism of Action of Triamcinolone
The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Additional Information of Triamcinolone
|Pharmacology Class:||Stomatological Preparations|
|Therapeutic Class:||Stomatological Preparations|
|Chemical Class:||Corticosteroids For Local Oral Treatment|
|Synonyms:||11Œ≤,16Œ±,17Œ±,21-tetrahydroxy-9Œ±-fluoro-1,4-pregnadiene-3,20-dione | 9-fluoro-11Œ≤,16Œ±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-11Œ≤,16Œ±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-11Œ≤,16Œ±,17Œ±,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-16Œ±-hydroxyprednisolone | Fluoxyprednisolone | Tiamcinolonum | Triamcinolona | Triamcinolonum|
Show All HSA-registered therapeutic products granted exemption to supply without prescription
HSA-Registered Products Containing Triamcinolone As a topical paste/lotion containing not more than 0.1%wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.